For example, progesterone receptor (PR)-positive patients are found to have a better survival rates than PR-negative patients [46], while breast cancers with human epidermal growth factor receptor 2 (HER2) overexpression may be treated with US Food and Drug Administration (FDA)-approved targeted therapy trastuzumab [47]. Here, ERBB2 is linked to breast carcinoma.